A novelcatalyticsystem based on copper(I) and chiral bis(phosphine) dioxides is described. This allows the arylation of silyl enol ethers to access enolizable α-arylated ketones in good yields and enantiomeric excess up to 95%. Noncyclic ketones are amenable substrates with this method, which complements other approaches based on palladium catalysis. Optimization of the ligand structure is accomplished
Enolamides, pharmaceutical compositions and methods for treating
申请人:Warner-Lambert Company
公开号:US04761424A1
公开(公告)日:1988-08-02
The present invention relates to novel enolamide type compounds, pharmaceutical compositions, and methods of use thereof, useful in the treatment of diseases in which products of lipoxygenase enzyme activity or the action of leukotrienes contribute to the pathological condition.
The Cyclopropane Ring as a Reporter of Radical Leaving-Group Reactivity for Ni-Catalyzed C(sp<sup>3</sup>)–O Arylation
作者:L. Reginald Mills、John J. Monteith、Gabriel dos Passos Gomes、Alán Aspuru-Guzik、Sophie A. L. Rousseaux
DOI:10.1021/jacs.0c06904
日期:2020.7.29
understand and predict reactivity is highly important for the development of new reactions. In the context of Ni-catalyzed C(sp3)-O functionalization, we have developed a unique strategy employing activated cyclopropanols to aid the design and optimization of a redox-active leavinggroup for C(sp3)-O arylation. In this chemistry, the cyclopropane ring acts as a reporter of leaving-group reactivity, since the
A facile entree to α-oxo sulfines by reaction of thionyl chloride with silyl enol ethers
作者:Bodo G. Lenz、Hendrik Regeling、Binne Zwanenburg
DOI:10.1016/s0040-4039(01)81728-7
日期:1984.1
Silyl enol ethers derived from 1-indanone, 2-indanone, α-tetralone and 4-chromanone react with thionylchloride to give α-oxo sulfines (3) which can be either isolated or trapped by a cycloaddition reaction with a diene.
Enolamides, pharmaceutical compositions and methods of use thereof for
申请人:Warner-Lambert Company
公开号:US04921871A1
公开(公告)日:1990-05-01
The present invention relates to novel enolamide type compounds, pharmaceutical compositions, and methods of use thereof, useful in the treatment of diseases in which products of lipoxygenase enzyme activity or the action of leukotrienes contribute to the pathological condition.